Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

202349 citationsJournal Articlehybrid Open Access

Authors

Shukui Qin · Nanjing General Hospital of Nanjing Military Command

Jin Li · Shanghai East Hospital

Yuxian Bai · Harbin Medical University

Zishu Wang · First Affiliated Hospital of Bengbu Medical College

Zhendong Chen · Anhui Medical University

Rui‐Hua Xu · Sun Yat-sen University

Jianming Xu

Abstract

In patients with locally advanced or metastatic K-Ras wild-type PC, nimotuzumab plus gemcitabine significantly improved OS and PFS with a good safety profile.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Neuroblastoma Research and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 33, pp. 5163-5173

DOI: 10.1200/jco.22.02630

Field-Weighted Citation Impact: 11.28